Levi Strauss & Co. vs Teladoc Health Inc — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while Teladoc Health Inc trades at $5.77 (market cap $1.01B). The key difference: Levi Strauss & Co. is far larger — about 7.2× Teladoc Health Inc's market cap, and Levi Strauss & Co. pays a 3.36% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Teladoc Health Inc for 39 Days on average.
| LEVI | TDOC | |
|---|---|---|
Market Cap | $7.31B | $1.01B |
Volume | 13,683,095 | 4,668,477 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $9.72 |
52-Week Low | $17.92 | $4.47 |
Typical Hold Time | 70 Days | 39 Days |
Enterprise Value | $8.86B | $1.27B |
Dividend Yield | 3.36% | — |
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $0.48 exceeding expectations. Valuation metrics appear attractive with a P/E of 12.53 and P/S of 1.12, while profitability remains solid with a net income margin of 8.83% and ROE of 25.76%.
Wall Street maintains a bullish stance with 15 buy ratings and a consensus price target of $29.00, implying significant upside. However, technical indicators show bearish momentum, and risks include competitive pressures and recent cybersecurity incidents. The stock's current price near recent support levels presents a potential entry point for value-oriented investors.
Teladoc Health (TDOC) trades at $5.77, up 3.78% today but remains near multi-year lows amid ongoing profitability challenges. The stock shows bearish technical signals with mixed earnings performance, having beaten estimates in two of the last three quarters but posting consistent net losses. Recent management changes include the appointment of a new CFO and legal officer as the company focuses on stabilizing its integrated care business while grappling with BetterHelp segment weakness.
While TDOC trades at discounted valuation multiples (P/S 0.4x, P/B 0.77x) and analysts maintain a $8.83 price target, the path to profitability remains uncertain given seven consecutive quarters of negative earnings. The primary investment thesis hinges on the company's ability to monetize its chronic care platform and achieve sustainable free cash flow generation, though investor sentiment remains cautious amid ongoing losses and competitive pressures in virtual healthcare.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →